High level of Ets-related gene expression has high specificity for prostate cancer: A tissue microarray study of 11483 cancers

Histopathology

Volumn 61, Issue 3, 2012, Pages 445-453

  Minner, Sarah ^a   Luebke, Andreas M ^a   Kluth, Martina ^a   Bokemeyer, Carsten ^a   Jänicke, Fritz ^a   Izbicki, Jakob ^a   Schlomm, Thorsten ^a   Sauter, Guido ^a   Wilczak, Waldemar ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

ERG; Prostate cancer; Specificity; Tissue microarray

Indexed keywords

ETS RELATED PROTEIN; TRANSCRIPTION FACTOR ETS; UNCLASSIFIED DRUG;

ANAPLASTIC CARCINOMA; ANGIOSARCOMA; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER TISSUE; CONTROLLED STUDY; DERMATOFIBROMA; DIAGNOSTIC TEST ACCURACY STUDY; ENDOTHELIUM CELL; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GENE OVEREXPRESSION; GIANT CELL TUMOR; HEMANGIOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPOSI SARCOMA; LIVER CELL CARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; OSTEOCLASTOMA; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE CARCINOMA; SENSITIVITY AND SPECIFICITY; SKIN CARCINOMA; TENDON SHEATH GIANT CELL TUMOR; TESTIS TERATOMA; THYMOMA; THYROID CARCINOMA; THYROID UNDIFFERENTIATED CARCINOMA; TISSUE MICROARRAY; TUMOR GENE; TUMOR LOCALIZATION; UTERUS CARCINOMA; VASCULAR TUMOR;

HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASMS; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS; TRANS-ACTIVATORS; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84865359787     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04240.x     Document Type: Article

References (22)

1. Vlaeminck-Guillem V, Carrere S, Dewitte F, Stehelin D, Desbiens X, Duterque-Coquillaud M. The Ets family member Erg gene is expressed in mesodermal tissues and neural crests at fundamental steps during mouse embryogenesis. Mech. Dev. 2000; 91; 331-335.
2. Loughran SJ, Kruse EA, Hacking DF et al. The transcription factor Erg is essential for definitive hematopoiesis and the function of adult hematopoietic stem cells. Nat. Immunol. 2008; 9; 810-819.
3. Birdsey GM, Dryden NH, Amsellem V et al. Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin. Blood 2008; 111; 3498-3506.
4. Dhordain P, Dewitte F, Desbiens X, Stehelin D, Duterque-Coquillaud M. Mesodermal expression of the chicken erg gene associated with precartilaginous condensation and cartilage differentiation. Mech. Dev. 1995; 50; 17-28.
5. Anderson KL, Smith KA, Perkin H et al. PU.1 and the granulocyte- and macrophage colony-stimulating factor receptors play distinct roles in late-stage myeloid cell differentiation. Blood 1999; 94; 2310-2318.
6. Shimizu K, Ichikawa H, Tojo A et al. An ets-related gene, ERG, is rearranged in human myeloid leukemia with t(16;21) chromosomal translocation. Proc. Natl Acad. Sci. USA 1993; 90; 10280-10284.
7. Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, Denny CT. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat. Genet. 1994; 6; 146-151.
8. Tomlins SA, Rhodes DR, Perner S et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310; 644-648.
9. Perner S, Demichelis F, Beroukhim R et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006; 66; 8337-8341.
10. Mertz KD, Setlur SR, Dhanasekaran SM et al. Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia 2007; 9; 200-206.
11. Iljin K, Wolf M, Edgren H et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res. 2006; 66; 10242-10246.
12. Park K, Tomlins SA, Mudaliar KM et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010; 12; 590-598.
13. Furusato B, Tan SH, Young D et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis. 2010; 13; 228-237.
14. Marx AH, Burandt EC, Choschzick M et al. Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Hum. Pathol. 2010; 41; 1577-1585.
15. Choschzick M, Lassen P, Lebeau A et al. Amplification of 8q21 in breast cancer is independent of MYC and associated with poor patient outcome. Mod. Pathol. 2010; 23; 603-610.
16. La Cour JM, Hoj BR, Mollerup J, Simon R, Sauter G, Berchtold MW. The apoptosis linked gene ALG-2 is dysregulated in tumors of various origin and contributes to cancer cell viability. Mol. Oncol. 2008; 1; 431-439.
17. Minner S, Enodien M, Sirma H et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of anti-hormonal therapy. Clin. Cancer Res. 2011; 17; 5878-5888.
18. Miettinen M, Wang ZF, Paetau A et al. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am. J. Surg. Pathol. 2011; 35; 432-441.
19. Park K, Tomlins SA, Mudaliar KM et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010; 12; 590-598.
20. Anderson MK, Hernandez-Hoyos G, Diamond RA, Rothenberg EV. Precise developmental regulation of Ets family transcription factors during specification and commitment to the T cell lineage. Development 1999; 126; 3131-3148.
21. Tapia C, Glatz K, Novotny H et al. Close association between HER-2 amplification and overexpression in human tumors of non-breast origin. Mod. Pathol. 2007; 20; 192-198.
22. Scheble VJ, Braun M, Beroukhim R et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod. Pathol. 2010; 23; 1061-1067.